Diabetic peripheral neuropathy therapy-induced activation of humoral serotonin and endogenous neurotrophins
https://doi.org/10.14412/2074-2711-2013-2333
Abstract
The indicators of pain and psychological status, the concentrations of serum serotonin and blood platelets, and the levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor were studied in 82 patients with diabetic peripheral neuropathy (DPN). Along with conventional treatment aimed to normalize carbohydrate metabolism, 30 patients with DPN received actovegin in an intravenous, jetwise dose of 10.0 ml for 10 days. Prior to treatment, their pain intensity was 5.94±1.2 and 29.6±6.24 scores according to a visual analogue scale (VAS) and PainDETECT, respectively. The subclinical level of anxiety and depression was noted. The amount of serotonin in the serum (90.39±55.43 ng/ml) and blood platelets (298.13±80.33 ng/ml) was lower than that in the control. The content of serum BDNF in DPN was also substantially lower (419.27±132.7 pg/ml; p<0.04) than that in the control. After treatment, the actovegin group showed a more significant reduction in pain syndrome according to the VAS (3.5±0.6 cm; p=0.005) and PainDETECT (19.4±4.1 scores, p=0.005), a decrease in the degree of anxiety and depression according to the Beck inventory (11.4±1.4 scores; p=0.001), and an increase in BDNF levels up to 979.71±289.9 pg/ml. Serum serotonin and blood platelets increased up to 206.13±78.3 and 477.06±114.45 ng/ml, respectively; which is indicative of the correct choice of the treatment for DPN.
About the Authors
Yuulia Vladimirovna Karakulova
Department of Neurology, Prof. V.P. Pervushin Faculty of Therapeutics, Acad. E.A. Vagner Perm State Medical Academy, Ministry of Health of Russia
Russian Federation
Russian Federation
N B Kaigorodova
Department of Neurology, Prof. V.P. Pervushin Faculty of Therapeutics, Acad. E.A. Vagner Perm State Medical Academy, Ministry of Health of Russia
Russian Federation
Russian Federation
E A Batueva
Department of Neurology, Prof. V.P. Pervushin Faculty of Therapeutics, Acad. E.A. Vagner Perm State Medical Academy, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. <div><p>Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care. 2004;27(6):1458–86. DOI: 10.2337%2Fdiacare.27.6.1458.</p><p>Ziegler D, Sohr CG, Nourooz-Zadeh J. Oxidative stress and antioxidant defense in relation to the severity of diabetic polyneuropathy and cardiovascular autonomic neuropathy. Diabetes Care. 2004;27(9):2178–83. DOI: 10.2337%2Fdiacare.27.9.2178.</p><p>Tesfaye S, Chaturvedi N, Eaton SE; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005;352(4):341–50. DOI: 10.1056%2FNEJMoa032782.</p><p>Яхно НН. Боль. Москва: МЕДпресс-информ; 2009. 303 с. [Yakhno NN. Bol'. Mosсow: MEDpress-inform; 2009. 303 p.]</p><p>Кукушкин МЛ., Хитров НК. Общая патология боли. Москва: Медицина; 2004. 144 с. [Kukushkin ML. Obshchaya patologiya boli. Moskva: Meditsina; 2004. 144 р.]</p><p>Данилов АБ. Нейропатическая боль. Москва: Боргес; 2007. 198 с. [Danilov AB. Neyropaticheskaya bol'. Moskva: Borges; 2007. 198 р.]</p><p>Каракулова ЮВ, Шутов АА. Изучение гуморального звена серотонинергической системы при хронических болевых синдромах. Росcийский журнал боли. 2011;2:10–1. [Karakulova YuV, Shutov AA. Izuchenie gumoral'nogo zvena serotoninergicheskoy sistemy pri khronicheskikh bolevykh sindromakh. Rosciyskiy zhurnal boli. 2011;2:10–1.]</p><p>Каракулова ЮВ, Шутов АА. Количественное определение серотонина сыворотки крови в диагностике головных болей напряжения. Клиническая и лабораторная диагностика. 2006;1:9–10. [Karakulova YuV, Shutov AA. Quantitative determination of serum serotonin in the diagnosis of tension headache. Klinicheskaya laboratornaya i diagnostika. 2006;1:9–10.]</p><p>Kroeze WK. The molecular biology of serotonin receptors therapeutic implication for the interface of mood and psychosis. Biol Psychiatry. 1998;44(11):1128–42. DOI: 10.1016%2FS0006-3223%2898%2900132-2.</p><p>Ткаченко АА. Содержание серотонина в плазме крови и тромбоцитах и показатели захвата серотонина тромбоцитами при нарушении половой идентичности у лиц с аномальным сексуальным поведением. Росcийский психиатрический журнал. 1997;3:37–40. [Tkachenko AA. Soderzhanie serotonina v plazme krovi i trombotsitakh i pokazateli zakhvata serotonina trombotsitami pri narushenii polovoy identichnosti u lits s anomal'nym seksual'nym povedeniem. Rosciyskiy psikhiatricheskiy zhurnal. 1997;3:37–40.]</p><p>Artigas F. Increased plasma free serotonin but unchanged platelet serotonin in bipolar patients treated chronically with lithium. Psychopharmacology (Berl). 1989;99(3):328–32. DOI: 10.1007%2FBF00445552.</p><p>Отеллин ВА. Формирование патологий головного мозга в эмбриональный период. Природа. 2003;(9):23–8. [Otellin VA. Formirovanie patologiy golovnogo mozga v embrional'nyy period. Priroda. 2003;(9):23–8.]</p><p>Гомазков ОА. Плейотропные эффекты нейротрофинов. Принципы терапевтического действия церебролизина. Москва: ООО КДМ; 2010. 136 с. [Gomazkov OA. Pleyotropnye effekty neyrotrofinov. Printsipy terapevticheskogo deystviya tserebrolizina. Moscow: OOO KDM; 2010. 136 р.]</p><p>Fujimura H, Altar C, Chen R et al. Brain-derived neurotrophic factor is stored in human platelets and released by agonist stimulation. Tromb Haemost. 2002;87(4):728–34.</p><p>Pearse AG. The common peptides and the citochemistry of their cells of origin. Basic Appl Histochem. 1980;24(2):63–73.</p><p>Lesch KP, Bengel D, Heils A et al. Assoсiation of anxiеty-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274(5292):1527–31.</p><p>Karege F, Perrez G, Bondolfi G et al. Decreased serum brain-derived neurutrophic factor levels in major depressed patients. Psychiatry Res. 2002;109(2):143–8. DOI: 10.1016%2FS0165-1781%2802%2900005-7.</p><p>Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573–81. DOI: 10.1016/j.pain.2010.06.019.</p><p>Строков ИА, Моргоева ФА. Стратегия профилактики и лечения неврологических осложнений сахарного диабета. В сб.: Опыт применения актовегина в эндокринологии. Москва; 2005. C. 47–55. [Strokov IA, Morgoeva FA. Strategiya profilaktiki i lecheniya nevrologicheskikh oslozhneniy sakharnogo diabeta. V sb.: Opyt primeneniya aktovegina v endokrinologii. Moscow; 2005. Р. 47–55.]</p><p>Dworkin RH, O'Connor AB, Backonja M et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(2):237–51. DPO: 10.1016%2Fj.pain.2007.08.033. Epub 2007 Oct 24.</p><p>Ziegler D, Movsesyan L, Mankovsky B et al. Treatment symptomatic polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care. 2009;32(8):1479–84. DOI: 10.2337/dc09-0545. Epub 2009 May 26.</p></div><br />
Review
For citations:
Karakulova YV, Kaigorodova NB, Batueva EA. Diabetic peripheral neuropathy therapy-induced activation of humoral serotonin and endogenous neurotrophins. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2013;5(3):13-17. (In Russ.) https://doi.org/10.14412/2074-2711-2013-2333
Views:
979
Email this article 